Results 61 to 70 of about 3,000,774 (406)

Neuroendocrine Tumor Markers

Frontiers in Neuroendocrinology, 2001
Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity).
Leo J. Hofland, F. R. E. Nobels, Steven W. J. Lamberts   +2 more
openaire   +2 more sources

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]

, 2016
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan, Peterson, P Gabriel, Quinn, Mary, Reid, Tony R, Schmitz, Bruno, Scicinski, Jan   +11 more
core   +7 more sources

Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?

Endocrine Connections, 2016
To date, the value of fasting plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) as potential novel biomarkers in patients with neuroendocrine tumors (NETs) is unknown.The aims of this study are to (i) compare fasting AG and UAG levels between ...
Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Richard A Feelders, Patric J D Delhanty, Wouter W de Herder, Piet Kramer   +6 more
doaj   +1 more source

Gastroenteropancreatic Neuroendocrine Tumors

Ca, 2018
Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in ...
M. Cives, J. Strosberg
semanticscholar   +1 more source

Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms”

Cancer Treatment and Research Communications, 2022
Background: Bone metastases (BM) are related to worse outcome in patients with neuroendocrine neoplasms (NENpts). Aim: Assess utility of serum tumor markers (STM) for detection of BM in lung NENpts.
Violetta Rosiek, Monika Wójcik-Giertuga, Beata Kos-Kudła   +2 more
doaj  

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]

, 2018
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto, Campana, Davide, Di Giacinto, Paola, Isidori, Andrea, Lania, Andrea, Lenzi, Andrea, Rizza, Laura, Rota, Francesca, Zuppi, Paolo   +8 more
core   +1 more source

Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract

Cancer Communications, Volume 42, Issue 12, Page 1367-1386, December 2022., 2022
Abstract Background Neuroendocrine carcinomas of the gastrointestinal tract (GI‐NECs) remain a disease of grim prognosis with limited therapeutic options. Their molecular characteristics are still undefined. This study aimed to explore the underlying genetic basis and heterogeneity of GI‐NECs.
Huanwen Wu, Zicheng Yu, Yueping Liu, Lei Guo, Lianghong Teng, Lingchuan Guo, Li Liang, Jing Wang, Jie Gao, Ruiyu Li, Ling Yang, Xiu Nie, Dan Su, Zhiyong Liang   +13 more
wiley   +1 more source

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA

Endocrine Connections, 2023
Background: Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival.
Peiwen Wu, Dongjie He, Hao Chang, Xiaozhi Zhang   +3 more
doaj   +1 more source

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

Journal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors (ICIs) revolutionized the management of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers.
Davide Ciardiello, Francesca Spada, Nicola Fazio, Maria Giulia Zampino, Lorenzo Gervaso, Rivadavio Antunes Oliveira, Michele Borghesani, Lorenzo Guidi, Lavinia Benini, Laura Algeri, Chiara Alessandra Cella   +10 more
doaj   +1 more source

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

New England Journal of Medicine, 2011
BACKGROUND The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
E. Raymond, L. Dahan, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, Denis Smith, A. Vinik, Jen‐Shi Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski   +19 more
semanticscholar   +1 more source